Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

BIIBBullishAnalyst Target Updateanalyst

Medium materiality4/10

RBC Capital raises Biogen price target to $272 from $256

Oct 29, 2026, 5:34 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

The upward target revision supports a modest bullish view, but the implied upside is limited and reflects one analyst's opinion.

AI summary

What happened, with direct paths to the underlying reporting

RBC Capital raised its BIIB price target to $272 from $256, about 8% above the posted price of $251.63.

RBC Capital raised its target by $16 to $272.
The target is about 8% above the posted $251.63 price.

Key facts

01
Target: $272
02
Posted price: $251.63
03
Analyst firm: RBC Capital

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

RBC Capital raises Biogen price target to $272 from $256

Key facts

Biogen Q3 earnings beat prompts price targets to $290

Biogen's litifilimab CLE shows durable skin clearance; Phase 3 readout in 1H 2027

Biogen-Eisai LEQEMBI IQLIK approval; diranersen Phase 2 data raises questions

FDA approves at-home starting dose for Leqembi, boosting access and uptake